Dr Reddy's Laboratories has reported a 17% decline in net profits at INR5.7bn ($93m) for the second quarter ended September, weighed down by higher operating expenses. Consolidated revenues for the period rose by 7% to INR35.9bn.
Expense-hit Dr Reddy's set for first NDA filing
Dr Reddy's Laboratories has reported a 17% decline in net profits at INR5.7bn ($93m) for the second quarter ended September, weighed down by higher operating expenses. Consolidated revenues for the period rose by 7% to INR35.9bn.
More from Dermatological
• By
CEO Carlos Gallardo tells Scrip the Barcelona-based group has laid the foundations to advance four promising assets that have considerable potential for a variety of dermatological diseases.
• By
Incyte’s JAK1 inhibitor meets the primary endpoint in two Phase III hidradenitis suppurativa trials, but the drug may not be able to supplant established biologic therapies.
• By
Having bested BMS's oral psoriasis drug Sotyktu, the closely watched once-daily IL-23 blocker is going head-to-head with J&J's own autoimmune mega-blockbuster Stelara.
• By
Swiss major gains global rights to preclinical asset as it joins race for MRGPRX2 antagonists in urticaria, where some same-class rivals are already in Phase II.
More from Therapy Areas
• By
The UK giant is forecasting peak sales of $5bn plus
• By
Novo’s semaglutide has shown its benefits as an injectable in patients with peripheral arterial disease and as an oral agent in cardiovascular outcomes, but stronger results are expected soon from Lilly’s tirzepatide.
• By
The small interference RNA therapeutic can be used by patients regardless of inhibitor status.